Discover how Python is evolving in 2025 with new tools, frameworks, and trends shaping AI, data science, and API development.
The FDA granted priority review for trastuzumab deruxtecan in combination with pertuzumab for first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback